Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease

Table 2 Association analysis of azathioprine and NUDT15 polymorphism

Genotype of NUDT15	C/C	C/T	Total	P value
No. of patients (gene frequencies)	64 (90.0)	16 (10.0)	80	-
Age in yr	33.69 ± 11.31	31.13 ± 12.40	33.18 ± 11.50	0.429
Sex, M/F	48/16	11/5	59/21	0.611
Disease stages
Remission	6 (9.4)	3 (18.8)	9 (11.3)	0.253
Mild activity	10 (15.6)	2 (12.5)	12 (15.0)
Moderate activity	35 (54.7)	5 (31.3)	40 (50.0)
Severe activity	13 (20.3)	6 (37.5)	19 (23.8)
Initial dosage of AZA in mg/kg daily	1.044 ± 0.318	1.241 ± 0.252	1.082 ± 0.441	0.596
Duration of AZA in mo	8.1 ± 11.19	9.3 ± 9.95	8.4 ± 10.90	0.686
Combined with corticosteroids	28 (43.8)	5 (31.3)	33 (41.3)	0.071
Combined with IFX	14 (21.9)	7 (43.8)	21 (26.3)
Combined with IFX and corticosteroid	0	1 (6.3)	1 (1.3)
Leukopenia	11 (17.2)	8 (50.0)a	19 (23.8)	0.006

Data are presented as n (%) or mean ± SD.

^aP < 0.05 vs NUDT15 C/C developed leukopenia. AZA: Azathioprine; IFX: Infliximab.